Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer

URN:NBN:SI:DOC-GA3EXV3O2022Choi, Jiwondocuments/doc/G/URN_NBN_SI_doc-GA3EXV3O_001.pdfdocuments/doc/G/URN_NBN_SI_doc-GA3EXV3O_001.txt256articlestr. 185-197, VIII10.2478/raon-2022-00121318-2099228816131URN:NBN:SI:doc-GA3EXV3OengCroatian Medical Association - Croatian Society of RadiologySlovenian Medical Society - Section of RadiologyRadiology and oncology (Ljubljana)BYbiološki zaviralec receptorja TGF beta tipa Iobsevanjeoksidativni stresonkologijapljučne metastazerak dojkrakave matične celicerakave zarodne celiceCo-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer